The past year has been filled with new and exciting improvements and novel treatment options in the field of oncology and hematology. The FDA has granted approval and accelerated approval to many new drugs and drug combinations, including the very first approval for patients with HER2-mutant non–small cell lung cancer, trastuzumab deruxtecan. This is a great time to reflect on the current treatment landscape and ponder what 2023 could have in store for future approvals and emerging treatment opt...

At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares the four abstracts which he believes will have the greatest impact on practice in the year to come. Oncology Data Advisor: Welcome to Oncology D...

An educational enduring live meeting series and online activity provided by i3 Health has demonstrated knowledge gains encompassing the nurse's perspective of evolving treatment paradigms in advanced renal cell carcinoma (RCC). Kidney cancer is among the top 10 most common cancers in the United States, accounting for approximately 4% of all cancer diagnoses in the US. The American Cancer Society predicted that in 2022, 79,000 new cases of kidney cancer would be diagnosed, with 13,920 of these ca...

From my perch atop the masthead at Oncology Data Advisor, I am awed by the dozens of oncology professionals who give freely of their time and expertise to inform our readership of the latest in their respective areas. Their efforts are what make ODA a premier online resource for all things in this ever-evolving field. My heartfelt thanks go to these wonderful colleagues without whom we would cease to be a publication. In this month's Editor's Letter, I would like to highlight a few of the outsta...

It is my pleasure to assume the post of Editor in Chief of Oncology Data Advisor for 2022. One of the perks of this role is the opportunity to speak directly to you, the readership, about everything we are up to here. Not only do we strive to give you trenchant summaries of the latest and most relevant oncology treatment breakthroughs in print, podcast, and video formats, but we also aim to give you insights into where our experts believe oncology is headed and what hurdles need to be cleared be...

In order to identify the continuing medical education needs and preferences of hematology/oncology fellows, i3 Health administered a survey to participants at several live CME-certified visiting faculty meetings. i3 Health intends to use the results gathered from the survey in the planning and implementation of CME-certified activities. Of the 54 participants who completed surveys, 80% felt that they had adequate time for self-education activities during their fellowship program, compared with 2...

In order to accurately recognize the continuing medical education (CME) needs and preferences of urology/oncology health care providers, i3 Health administered a survey to participants at the 66th Society of Government Service Urologists Kimbrough Urological Seminar. The results obtained from the survey will be used by i3 Health in the planning and implementation of CME-approved activities. Of the 22 participants who completed the survey, 72.7% were urologists, 18.2% were residents, 4.5% were fe...

​Burnout is widespread in oncology, occurring in around 25% to 35% of medical oncologists, 28% to 36% of surgical oncologists, and 28% of radiation oncologists. In his previous interview with i3 Health, Daniel C. McFarland, DO, a medical oncologist and psychiatrist at Memorial Sloan Kettering Cancer Center in New York City, discussed what can be done about the high rates of suicide among physicians and the particularly high rates of depression among oncologists. In this second installment, he di...